PR91623

DENVER, Sept. 14, 2021 /PRNewswire=KYODO JBN/ --

Because elderly patients with non-small cell lung cancer are likely to be

excluded from clinical trials due to their lower functional capacity or

comorbidities, survival benefit from immune checkpoint inhibitors (ICIs)

remains unclear. In patients with non-small cell lung cancer (NSCLC), ICIs have

become one of the standard pharmacological therapies, but elderly patients may

be denied these therapies in clinical trials.

However, a new study presented today at the IASLC 2021 World Conference on Lung

Cancer suggests age does not negatively impact on survival benefit from ICIs

with stage IV NSCLC.

Dr. S. Takamori from the National Hospital Organization, Kyushu Cancer Center,

Kyushu, Japan and co-researchers analyzed 86,173 patients with stage IV

NSCLC--24,136 patients were age 75 and older and 62,037 patients were under age

75.

Multivariable Cox modeling confirmed the survival benefit from ICIs for

patients 75 years of age and older with stage IV NSCLC (HR: 0.61, 95% CI:

0.58-0.65, P < 0.0001). The corresponding hazard ratio in patients under age 75

was 0.68. Despite the known negative prognostic factor, the impact of age (75

years of age or older) on overall survival by univariate analysis was smaller

in those with ICIs than in those without (HR 1.23 vs. 1.32).

"Chronological age does not appear to impact on survival benefit of ICIs in

stage IV NSCLC according to our large database analysis," reported Dr.

Takamori. These findings should be validated in future prospective studies.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only

global organization dedicated solely to the study of lung cancer and other

thoracic malignancies. Founded in 1974, the association's membership includes

more than 7,500 lung cancer specialists across all disciplines in over 100

countries, forming a global network working together to conquer lung and

thoracic cancers worldwide. The association also publishes the Journal of

Thoracic Oncology, the primary educational and informational publication for

topics relevant to the prevention, detection, diagnosis, and treatment of all

thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:

The WCLC is the world's largest meeting dedicated to lung cancer and other

thoracic malignancies, attracting more than 7,000 researchers, physicians and

specialists from more than 100 countries. The goal is to increase awareness,

collaboration and understanding of lung cancer, and to help participants

implement the latest developments across the globe. The conference will cover a

wide range of disciplines and unveil several research studies and clinical

trial results. For more information, visit https://wclc2021.iaslc.org/.

Contact: Chris Martin, IASLC Media Relations, cmartin@davidjamesgroup.com

SOURCE: IASLC